L

Lytix Biopharma AS
OSE:LYTIX

Watchlist Manager
Lytix Biopharma AS
OSE:LYTIX
Watchlist
Price: 6.8 NOK -0.29% Market Closed
Market Cap: 337.4m NOK
Have any thoughts about
Lytix Biopharma AS?
Write Note

Lytix Biopharma AS
Free Cash Flow

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Lytix Biopharma AS
Free Cash Flow Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Free Cash Flow CAGR 3Y CAGR 5Y CAGR 10Y
L
Lytix Biopharma AS
OSE:LYTIX
Free Cash Flow
-kr96m
CAGR 3-Years
-58%
CAGR 5-Years
-6%
CAGR 10-Years
N/A
Hofseth Biocare ASA
OSE:HBC
Free Cash Flow
-kr57.7m
CAGR 3-Years
18%
CAGR 5-Years
N/A
CAGR 10-Years
4%
B
Bergenbio ASA
OSE:BGBIO
Free Cash Flow
-kr139m
CAGR 3-Years
21%
CAGR 5-Years
6%
CAGR 10-Years
N/A
Arcticzymes Technologies ASA
OSE:AZT
Free Cash Flow
-kr9.5m
CAGR 3-Years
N/A
CAGR 5-Years
-26%
CAGR 10-Years
-4%
N
Nykode Therapeutics ASA
OSE:NYKD
Free Cash Flow
-$88.5m
CAGR 3-Years
N/A
CAGR 5-Years
-58%
CAGR 10-Years
N/A
T
Thor Medical ASA
OSE:TRMED
Free Cash Flow
-kr27.6m
CAGR 3-Years
59%
CAGR 5-Years
40%
CAGR 10-Years
3%
No Stocks Found

Lytix Biopharma AS
Glance View

Market Cap
337.4m NOK
Industry
Biotechnology

Lytix Biopharma AS develops novel drugs for the treatment of resistant bacterial and fungal infections, as well as oncology treatments. The company is headquartered in Oslo, Oslo. The company went IPO on 2021-06-14. The firm's product, LTX-315, is a oncolytic molecule representing a new and superior in situ therapeutic vaccination principle to boost anti-cancer immunity, with the potential to be the ideal combination partner with other types of immunotherapy. LTX-315 targets cancer cells and disintegrates their cell membranes, causing immunogenic cell death and release of a patient’s tumor specific antigens. This mode of action allows cytotoxic T cells to recognize, infiltrate, and attack cancer cells. The firm serves customers domestically.

LYTIX Intrinsic Value
0.9 NOK
Overvaluation 87%
Intrinsic Value
Price
L

See Also

What is Lytix Biopharma AS's Free Cash Flow?
Free Cash Flow
-96m NOK

Based on the financial report for Dec 31, 2023, Lytix Biopharma AS's Free Cash Flow amounts to -96m NOK.

What is Lytix Biopharma AS's Free Cash Flow growth rate?
Free Cash Flow CAGR 5Y
-6%

Over the last year, the Free Cash Flow growth was -82%. The average annual Free Cash Flow growth rates for Lytix Biopharma AS have been -58% over the past three years , -6% over the past five years .

Back to Top